A
2.43
0.06 (2.53%)
| Previous Close | 2.37 |
| Open | 2.50 |
| Volume | 500,690 |
| Avg. Volume (3M) | 1,655,090 |
| Market Cap | 64,402,020 |
| Price / Book | 2.37 |
| 52 Weeks Range | |
| Earnings Date | 12 Aug 2025 - 18 Aug 2025 |
| Diluted EPS (TTM) | -2.24 |
| Current Ratio (MRQ) | 10.68 |
| Operating Cash Flow (TTM) | -22.96 M |
| Levered Free Cash Flow (TTM) | -13.95 M |
| Return on Assets (TTM) | -91.05% |
| Return on Equity (TTM) | -280.78% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bullish | Mixed |
| Biotechnology (Global) | Bullish | Mixed | |
| Stock | Annovis Bio, Inc. | Mixed | Bearish |
AIStockmoo Score
0.4
| Analyst Consensus | 2.0 |
| Insider Activity | NA |
| Price Volatility | -2.0 |
| Technical Moving Averages | 3.5 |
| Technical Oscillators | -2.0 |
| Average | 0.38 |
|
Annovis Bio Inc is a clinical-stage pharmaceutical company focused on developing and commercializing drugs for the treatment of Parkinson's and Alzheimer's diseases and other neurodegenerative diseases. The pipeline products of the company consists of: Buntanetap for chronic neurodegeneration - including AD and PD; ANVS405 for acute neurodegeneration; and ANVS301 for AD. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 14.69% |
| % Held by Institutions | 16.09% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Merit Financial Group, Llc | 31 Dec 2025 | 81,316 |
| Wescott Financial Advisory Group, Llc | 31 Dec 2025 | 41,607 |
| First National Trust Co | 31 Dec 2025 | 40,000 |
No data within this time range.
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 18 Dec 2025 | Announcement | Annovis Announces Open-Label Extension Study for Parkinson's Disease Patients |
| 16 Dec 2025 | Announcement | Annovis to Host Corporate Update Webinar on January 28, 2026 |
| 03 Dec 2025 | Announcement | Annovis To Present at the 2025 Annual Meeting of the Parkinson Study Group |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |